"Second interim analysis of RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC)."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Second interim analysis of RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

6081Background: Sorafenib and lenvatinib are oral MKIs approved for the treatment of RAI-R DTC; however, there is no consensus on when patients with asymptomatic RAI-R DTC should start treatment wi... Click to show full abstract

Keywords: patients asymptomatic; treatment; interim analysis; second interim; rai dtc

Journal Title: Journal of Clinical Oncology
Year Published: 2018

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
0

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended